Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Drappatz

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
International Journal of Radiation Oncology, Biology, Physics|June 3, 2008
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiformeJan Drappatz, Eric T Wong, David Schiff, et al.
Neuro-Oncology|April 25, 2007
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adultsSantosh Kesari, David Schiff, Lisa Doherty, et al.
Journal of Neuro-Oncology|January 25, 2017
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomasLakshmi Nayak, John de Groot, Jeffrey S Wefel, et al.
Journal of Neuro-Oncology|October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Journal of Neurosurgery|March 5, 2013
Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical articleMarlon G Saria, Courtney Corle, Jethro Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERTManmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
International Journal of Radiation Oncology, Biology, Physics|June 3, 2008
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiformeJan Drappatz, Eric T Wong, David Schiff, et al.
Neuro-Oncology|April 25, 2007
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adultsSantosh Kesari, David Schiff, Lisa Doherty, et al.
Journal of Neuro-Oncology|January 25, 2017
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomasLakshmi Nayak, John de Groot, Jeffrey S Wefel, et al.
Journal of Neuro-Oncology|October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Journal of Neurosurgery|March 5, 2013
Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical articleMarlon G Saria, Courtney Corle, Jethro Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERTManmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, et al.
Pageof 13